Cargando…
Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
INTRODUCTION: Severe uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual’s quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment. OBJECTIVE: To review the curre...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422446/ https://www.ncbi.nlm.nih.gov/pubmed/33867274 http://dx.doi.org/10.1016/j.bjorl.2021.03.003 |
_version_ | 1784777813702737920 |
---|---|
author | Anselmo-Lima, Wilma T. Tamashiro, Edwin Romano, Fabrizio R. Miyake, Marcel M. Roithmann, Renato Kosugi, Eduardo M. Nakanishi, Márcio Fornazieri, Marco A. Bezerra, Thiago F.P. Mello, João F. Lessa, Marcus M. Voegels, Richard L. Piltcher, Otávio B. Sakano, Eulalia Valera, Fabiana C.P. |
author_facet | Anselmo-Lima, Wilma T. Tamashiro, Edwin Romano, Fabrizio R. Miyake, Marcel M. Roithmann, Renato Kosugi, Eduardo M. Nakanishi, Márcio Fornazieri, Marco A. Bezerra, Thiago F.P. Mello, João F. Lessa, Marcus M. Voegels, Richard L. Piltcher, Otávio B. Sakano, Eulalia Valera, Fabiana C.P. |
author_sort | Anselmo-Lima, Wilma T. |
collection | PubMed |
description | INTRODUCTION: Severe uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual’s quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment. OBJECTIVE: To review the current status of biologic treatment indications in chronic rhinosinusitis. METHODS: The Brazilian Academy of Rhinology brought together different specialists to suggest a course of action, considering its particularities and aspects related to the national reality. RESULTS: Of particular interest for decision making will be the identification of subgroups of patients refractory to pre-existing treatment options and the construction of a strategy that improves their quality of life, with the best cost-benefit ratio. CONCLUSION: The use of biologics is a valid option for treatment in more severe cases. This strategy must be better understood and improved in the future, with more studies and greater clinical experience. |
format | Online Article Text |
id | pubmed-9422446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-94224462022-08-31 Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil Anselmo-Lima, Wilma T. Tamashiro, Edwin Romano, Fabrizio R. Miyake, Marcel M. Roithmann, Renato Kosugi, Eduardo M. Nakanishi, Márcio Fornazieri, Marco A. Bezerra, Thiago F.P. Mello, João F. Lessa, Marcus M. Voegels, Richard L. Piltcher, Otávio B. Sakano, Eulalia Valera, Fabiana C.P. Braz J Otorhinolaryngol Review Article INTRODUCTION: Severe uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual’s quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment. OBJECTIVE: To review the current status of biologic treatment indications in chronic rhinosinusitis. METHODS: The Brazilian Academy of Rhinology brought together different specialists to suggest a course of action, considering its particularities and aspects related to the national reality. RESULTS: Of particular interest for decision making will be the identification of subgroups of patients refractory to pre-existing treatment options and the construction of a strategy that improves their quality of life, with the best cost-benefit ratio. CONCLUSION: The use of biologics is a valid option for treatment in more severe cases. This strategy must be better understood and improved in the future, with more studies and greater clinical experience. Elsevier 2021-04-03 /pmc/articles/PMC9422446/ /pubmed/33867274 http://dx.doi.org/10.1016/j.bjorl.2021.03.003 Text en © 2021 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Article Anselmo-Lima, Wilma T. Tamashiro, Edwin Romano, Fabrizio R. Miyake, Marcel M. Roithmann, Renato Kosugi, Eduardo M. Nakanishi, Márcio Fornazieri, Marco A. Bezerra, Thiago F.P. Mello, João F. Lessa, Marcus M. Voegels, Richard L. Piltcher, Otávio B. Sakano, Eulalia Valera, Fabiana C.P. Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil |
title | Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil |
title_full | Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil |
title_fullStr | Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil |
title_full_unstemmed | Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil |
title_short | Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil |
title_sort | guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (crswnp) in brazil |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422446/ https://www.ncbi.nlm.nih.gov/pubmed/33867274 http://dx.doi.org/10.1016/j.bjorl.2021.03.003 |
work_keys_str_mv | AT anselmolimawilmat guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT tamashiroedwin guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT romanofabrizior guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT miyakemarcelm guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT roithmannrenato guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT kosugieduardom guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT nakanishimarcio guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT fornazierimarcoa guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT bezerrathiagofp guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT mellojoaof guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT lessamarcusm guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT voegelsrichardl guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT piltcherotaviob guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT sakanoeulalia guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil AT valerafabianacp guidelinefortheuseofimmunobiologicalsinchronicrhinosinusitiswithnasalpolypscrswnpinbrazil |